U.S., Nov. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07938138) titled 'Safety and Tolerability of F012 in Patients With Hyperuricemia and Gout' on Nov. 02.
Brief Summary: This study is a randomized, double-blind, placebo-controlled single dose escalation (SAD) study conducted in patients with hyperuricemia with or without gout. The plan is to conduct ramp ups in 5 dose groups of 1mg, 2mg, 4mg, 6mg, and 8mg (adjustable during the study), with 8 subjects in each dose group and a total of 40 subjects. The sentinel method will be used for each dose group, with 2 subjects in the first group (1A+1P) followed by 6 subjects in the second group (5A+1P), to observe safety and tolerability.
Study Start Date: Jun...